May, 2026 – Medtronic announced that its BrainSense™ and Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI) technologies are now licensed in Canada, expanding access to a new generation of personalized therapy for people living with Parkinson’s disease.

Recognized by TIME as one of the 2025 Best Inventions, BrainSense™ and Adaptive DBS is Canada’s first closed-loop DBS system—automatically adjusting therapy in real time based on a patient’s own brain activity. This milestone underscores both the technology’s innovation and its potential to transform the way Parkinson’s disease is managed.

More than 10 million people worldwide are living with Parkinson’s disease**, a progressive neurological condition with no cure. For over 30 years, deep brain stimulation (DBS) has helped patients manage symptoms by delivering targeted electrical stimulation to specific areas of the brain.

With BrainSense™ and Adaptive DBS, Medtronic is advancing this therapy further. Built on the Percept™ platform, the system continuously senses and interprets brain signals, enabling clinicians to better understand a patient’s condition over time while automatically adapting therapy in daily life. This reduces the need for manual adjustments and helps deliver a more responsive, personalized treatment experience.

Medtronic spent more than two decades developing this sensing-enabled system, integrating therapeutic brain-computer interface (BCI) technology into DBS. The result is the largest commercial application of BCI technology to date in this field—marking a significant step forward in personalized neuromodulation.

“Innovation has the power to fundamentally change what’s possible for patients,” said Rob Clifton, President of Medtronic Canada. “With BrainSense™ Adaptive DBS, we’re equipping healthcare professionals with meaningful, real-time insights and tools that can more precisely tailor therapy—helping improve patient outcomes and quality of life. This is a powerful example of how technology can bring us closer to truly personalized care.”

The availability of BrainSense™ and Adaptive DBS in Canada reinforces Medtronic’s commitment to advancing innovation while expanding access to life-changing therapies for patients throughout the country.

Patients considering DBS therapy should consult with a qualified healthcare provider to determine appropriate treatment options.

*Data on file
**According to: American Parkinson’s Disease Association, UK Dementia Research Institute and World Health Organization